Neutrophil elastase as a biomarker for bacterial infection in COPD

[1]  M. Giovannoni,et al.  A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications , 2019, Expert opinion on therapeutic patents.

[2]  S. Marshall,et al.  Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease , 2018, The Journal of allergy and clinical immunology.

[3]  J. Chalmers,et al.  Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease , 2017, Expert review of molecular diagnostics.

[4]  S. Marshall,et al.  Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis , 2017, American journal of respiratory and critical care medicine.

[5]  G. Brusselle,et al.  Sputum Neutrophil Elastase as a Biomarker for Disease Activity in Bronchiectasis. , 2017, American journal of respiratory and critical care medicine.

[6]  F. Accurso,et al.  Biomarkers for cystic fibrosis drug development. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  C. Vogelmeier,et al.  Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction , 2015, Respiratory Research.

[8]  C. Taggart,et al.  The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung , 2015, Mediators of inflammation.

[9]  I. Pavord,et al.  Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function , 2015, International journal of chronic obstructive pulmonary disease.

[10]  N. Forsyth,et al.  Measurement of C-reactive protein, procalcitonin and neutrophil elastase in saliva of COPD patients and healthy controls: correlation to self-reported wellbeing parameters , 2015, Respiratory Research.

[11]  O. Eickelberg,et al.  Autoprocessing of neutrophil elastase near its active site reduces the efficiency of natural and synthetic elastase inhibitors , 2015, Nature Communications.

[12]  C. Schumann,et al.  Conduct of a biomarker study in bronchiectasis patients: Correlation of neutrophil elastase activity and inflammatory load in induced sputum , 2014 .

[13]  I. Pavord,et al.  Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations , 2014, Chest.

[14]  A. Condliffe,et al.  The neutrophil in chronic obstructive pulmonary disease. , 2013, American journal of respiratory cell and molecular biology.

[15]  R. Stockley,et al.  Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. , 2013, Respiratory medicine.

[16]  M. Radic,et al.  Neutrophil Extracellular Traps: Double-Edged Swords of Innate Immunity , 2012, The Journal of Immunology.

[17]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[18]  Alberto Mantovani,et al.  Neutrophils in the activation and regulation of innate and adaptive immunity , 2011, Nature Reviews Immunology.

[19]  P. Gibson,et al.  Innate Immune Responses Are Increased in Chronic Obstructive Pulmonary Disease , 2011, PloS one.

[20]  M. Horwitz,et al.  Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases , 2010, Pharmacological Reviews.

[21]  Ruth Tal-Singer,et al.  Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study , 2010, Respiratory research.

[22]  O. Uzun,et al.  Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease , 2008, International journal of chronic obstructive pulmonary disease.

[23]  J. Eason,et al.  Research Corner Outcomes in Cardiopulmonary Physical Therapy: Chronic Respiratory Disease Questionnaire (CRQ) , 2008, Cardiopulmonary physical therapy journal.

[24]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[25]  Christine T. N. Pham,et al.  Neutrophil serine proteases: specific regulators of inflammation , 2006, Nature Reviews Immunology.

[26]  G. Salvesen,et al.  The protein structures that shape caspase activity, specificity, activation and inhibition. , 2004, The Biochemical journal.

[27]  D. Chaplin.  Overview of the immune response. , 2003, The Journal of allergy and clinical immunology.

[28]  A. Belaaouaj.  Neutrophil elastase-mediated killing of bacteria: lessons from targeted mutagenesis. , 2002, Microbes and infection.

[29]  R. Djukanović,et al.  Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation , 2002, European Respiratory Journal.

[30]  R. Boyton,et al.  Pulmonary defences to acute respiratory infection. , 2002, British medical bulletin.

[31]  I. Pavord,et al.  Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. , 2001, Respiratory medicine.

[32]  T. Murphy,et al.  Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review , 2001, Clinical Microbiology Reviews.

[33]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[34]  S. Sethi.  Bacterial infection and the pathogenesis of COPD. , 2000, Chest.

[35]  J. Ruiz,et al.  Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. , 1995, American journal of respiratory and critical care medicine.

[36]  F. Berkowitz.  Antibiotic resistance in bacteria. , 1995, Southern medical journal.

[37]  G. Döring.  The role of neutrophil elastase in chronic inflammation. , 1994, American journal of respiratory and critical care medicine.

[38]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[39]  G. Simone.  Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350. , 2019 .

[40]  F. Bai,et al.  Neutrophil in viral infections, friend or foe? , 2013, Virus research.

[41]  P. Calverley,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.